Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients
Launched by THAI GYNECOLOGIC ONCOLOGY COLLABORATIVE GROUP · Oct 22, 2009
Trial Information
Current as of June 25, 2025
Unknown status
Keywords
ClinConnect Summary
According to FIGO classification of cervical cancer, stage Ib2 was classified as clinically visible lesion more than 4.0 cm in greatest dimension and stage IIb was classified tumor invades parametrium must not to pelvic wall. These were the common stages in Thai cervical cancer patients,and made a troublesome effect to Thai women. According to this study,stage early IIb with 1/3 of parametrium involvement. Mostly these two stage was treated with concurrent chemoradiation, challenging the possibility of late sequelae of radiation effect. This specific group of patients can be avoid the refer...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Cervical cancer patients with FIGO stage Ib2-early IIb
- • Pathological proven squamous cell carcinoma or adenocarcinoma or adenosquamous cell carcinoma
- • ECOG performance status 0-1
- • No previous treatment for cervical cancer
- • Acceptable hematological,renal,liver function
- Exclusion Criteria:
- • Previous history of cancer
- • Underlying disease not fit for surgery
- • Psychological problem
- • Obvious pelvic/para-aortic node involvement
- • Pregnancy
- • HIV positive
- • History of bowel obstruction
About Thai Gynecologic Oncology Collaborative Group
The Thai Gynecologic Oncology Collaborative Group is a dedicated consortium of healthcare professionals and researchers focused on advancing the field of gynecologic oncology in Thailand. Committed to improving patient outcomes through innovative research and clinical trials, the group collaborates with leading institutions and experts to enhance the understanding, prevention, and treatment of gynecologic cancers. By fostering a multidisciplinary approach and promoting evidence-based practices, the Thai Gynecologic Oncology Collaborative Group aims to elevate the standards of care for women affected by these diseases and contribute to the global body of knowledge in gynecologic oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hat Yai, Songkhla, Thailand
Patients applied
Trial Officials
Saibua B. Chichareon, MD.
Principal Investigator
Thai Gynecologic Oncology Collaborative Group (TGOC)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials